BDTX Dec 2024 2.500 call
| Previous Close | 2.8000 |
| Open | 2.8000 |
| Bid | 2.2000 |
| Ask | 2.8500 |
| Strike | 2.50 |
| Expire Date | 2024-12-20 |
| Day's Range | 2.8000 - 2.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 19 |
Simply Wall St.Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Insider MonkeyIs Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry […]
GlobeNewswireBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology
